Update on Spontaneous Bacterial Peritonitis

Andrea Holguín Cardona, 1 Juan José Hurtado Guerra, 1 Juan Carlos Restrepo Gutiérrez, MD. 2

Abstract
Spontaneous bacterial peritonitis (SBP) is a serious complication that occurs among cirrhotic patients with ascites. It is a major cause of the high rates of mortality among these patients and has high rates of recurrence. Early diagnosis and optimal treatment can result in considerable improvements. It is noteworthy that high rates of prevalence of SBP have even been documented in asymptomatic patients. Primary and secondary prophylaxis are of great significance for improving patients chances of survival and for decreasing the initial incidence and recurrence of SBP. Nevertheless, treatment must be applied with great rigor and patients must be monitored carefully to prevent the development of antibiotic resistance. Some of determinants for treatment with antibiotics are previous episode(s) of SBP, digestive tract, evidence of hepatic dysfunction, low concentrations of proteins in ascetic fluid and hyperbilirubinemia. This updates is based on a review of the medical literature about SBP published in both Spanish and English over the last five years and available in major biomedical databases (PubMed, ClinicalKey, EBSCO, Scielo, Scopus and OVID). Our review revealed that there are very few publications in Colombia and the rest of Latin America and Colombia, some of which were written by the authors and their workgroup.

Keywords
Peritonitis, spontaneous bacterial peritonitis, bacterial translocation, cirrhosis, ascites.

DEFINITION
Although Spontaneous Bacterial Peritonitis had been reported earlier, SBP was first defined by Dr. Harold O. Connen in 1964 who identified it as an infection of the peritoneal fluid with no obvious source within the abdomen that is liable to surgical treatment (1-3). SPB is diagnosed when a culture is positive for ascites and there is a high count of polymorphonuclear leukocytes (PMN).

EPIDEMIOLOGY
Worldwide, bacterial infections occur in 25% to 30% of cirrhotic patients and are responsible for 30% to 50% of the mortality in patients with chronic liver disease (4, 5). In Latin America, the prevalence is similar: it ranges from 11.1% to 37.1% with mortality figures ranging from 21.9% to 32% (6-8). A study conducted in Colombia more than 20 years ago documented SPB prevalence at 27.2% with a mortality rate of 27.3% (9).

At one year of follow up of cirrhotic patients with ascites, the incidence of SBP is 10% to 25%. When routine diagnostic paracentesis is done on asymptomatic cirrhotic patients who have ascites at the time of admission to hospital, the incidence of SBP is 10% to 27% (10). In addition, the prevalence of SBP in asymptomatic cirrhotic patients in outpatient settings is 1.5% to 3.5% (11, 12). Bacterascites is found in 1.9% of these patients, but this figure rises to 11% among hospitalized patients (12, 13).
In the first descriptions of SBP, it was associated with mortality rates that could be as high as 90%, but this situation has improved considerably. Now the mortality rate is about 20% in standard scenarios (12, 14, 15). Still, hospitalized patients who are clinically decompensated have a probability of death during the first episode of SBP ranging from 10% to 50% (16, 17). This situation is attributed to acute deterioration of liver function more than to sepsis than itself which is responsible for only one third of these deaths (17).

After the first episode of SBP, the mortality rate within the next year is 70%, and the mortality rate in the second year is 80% (10). About 70% of SBP cases occur in patients with advanced cirrhosis (Child-Pugh Stage C) (10). In addition, recurrence rates a year after a first episode of SBP are as high as 40% to 70% (10, 18, 19).

SBP is considered to have been acquired during hospitalization when symptoms occur 72 hours after admission. In these cases, the infection is considered to be an independent risk factor for hospital mortality. Within 30 days of diagnosis, the mortality rate can be as high as 58.7% compared to a 30-day mortality rate of 37.3% for infections acquired in the community (20).

PATHOGENESIS

Initially the term “spontaneous” was used because the cause of the infection was not clearly identifiable (1). Over time it has been partially clarified (18, 21-23).

Many factors contribute to the pathogenesis of SBP. One of them is bacterial translocation that consists of passage of bacteria from the intestinal lumen to mesenteric lymph nodes. This process is favored by three main factors: bacterial overgrowth, alteration of the intestinal mucosal, and impaired local and systemic immunity (24-27). Bacterial overgrowth itself is favored by the impaired motility of the small intestine (28, 29) and functional changes in the intestinal mucosa are explained by increased permeability (30, 31).

The low concentration of hydrochloric acid produced by the use of proton pump inhibitors (PPIs) in cirrhotic patients is another factor. Some studies have found that patients have cirrhosis and who are using PPIs have three times the risk of cirrhotic patients who do not use PPIs of developing SBP (OR 4.23, 95% CI: 1.82 - 2.77) (32).

Studies have shown that bacterial translocation increases in cirrhotic patients (33-35) because of reduced local immunity that prevents bacterial clearance so that the bacteria is able to infect the mesenteric lymph nodes from where they can circulate systemically causing bacteremia (36). More frequent and longer lasting bacteremia occurs in cirrhotic patients because of their immunosuppressed states which are principally due to hypoalbuminemia and because of portosystemic shunts with alter the functioning of the mononuclear phagocyte system (10, 36, 37).

DIAGNOSIS

The most common symptoms are fever (68%), altered mental states (61%), abdominal pain (46%), gastrointestinal bleeding, chills, nausea and emesis (12). Nevertheless, it should be remembered that up to 30% of patients with SBP are completely asymptomatic (10, 14, 38). For this reason, all cirrhotic patients with ascites who are admitted to the hospital should undergo diagnostic paracentesis to remove ascitic fluid regardless of their clinical condition (4, 11). Fluid should be cultured for aerobic and anaerobic bacteria and Gram stained (although it has been reported to have a sensitivity of only 10%, it has a specificity of 97.5%) (39). Total and differential cell counts should be done. Cytochemistry should measure LDH, albumin, glucose, amylase and bilirubin (If indicated by observation of dark or yellow-brown color.) (40). As far as possible, ascites fluid must be sampled before the start of antibiotics except when the patient is in a septic shock in which case antibiotics should be started within 45 minutes (41).

SBP diagnosis is based on analysis of ascitic fluid (42, 43). A neutrophil count over 250/mm³ is sufficient to diagnose SBP regardless of the outcome of the culture. Cultures will be negative in 40% to 60% of cases according to the worldwide literature which is consistent with Latin American reports ranging from 26.9 and 59% (6, 44, 45). In contrast, negative culture reports from Colombia are as high as 78% (46). This may be due both to the small number of bacteria in the inoculum (usually <1 bacterial cell/mL) and to the presence of confounding factors (13). Since these may include start of antibiotics prior to diagnostic paracentesis and/or poor technique in administration of antibiotics the same, it has been suggested that samples for culturing be bottled at the bedside when there is high clinical suspicion and negative cultures (10, 11, 47-50).

In addition, it has been reported that only half of patients with SBP presented positive blood cultures (2), and there are even studies in which positive blood cultures are reported in only in 25% of patients (9). Some have suggested taking 500 neutrophils/mm³ as the cutoff point for diagnosis. This would increase specificity at the expense of sensitivity (11).

In general, the microorganisms that have been described as causes are, in descending order, E. coli, Klebsiella Pneumoniae, Streptococcus Spp, Enterococcus faecalis, E. faecium, Enterobacter Cloacae and Staphylococcus aureus (Table 1) (13, 45, 50-56).

In Latin America, E. coli isolates are the most common with percentages that range from 25.5% to a 71.4% (45, 54,
56), but there are reports in which up to 54% of cases of SBP are associated with Gram-positive bacteria (6).

A study conducted in Bogotá, Colombia between 2009 and 2013 found that the main microorganism isolated was Escherichia coli. This was treated with ampicillin and sulbactam in 65% of cases of which 39% required changes in treatment (46).

Bacteriascitis is another possible scenario. This occurs when the ascites PMN count is less than 250/mm³ and can be due to a secondary colonization of the ascitic fluid by an extraperitoneal infection. This may be a transient and spontaneously reversible colonization or it may be the first stage of SBP (11, 23).

The PMN count varies according to the infecting bacteria: it is lower for patients with SBP due to staphylococcus spp. (87 ± 200 PMN/mm³) than for patients with SBP due to streptococcus spp. (650 ± 1359 PMN/mm³), enterococcus spp. (771 ± 1686 PMN/mm³) and enterobacteria- ceae spp. (8342 ± 3275 PMN/mm³) (57).

In patients with hemorrhagic ascites (red blood cell count > 10,000/mm³), one PMN per 250 erythrocytes/mm³ must be subtracted. (4, 40) When lymphocytosis is predominant in ascites, the differential diagnosis should include tubercular peritonitis, neoplasms, congestive heart failure, pancreatitis and myxedema. In general, this condition is not related to SBP (4, 5, 11, 38).

Other methods have been used to diagnose SBP. Reactive strips have a sensitivity ranging from 45% to 100%, a specificity ranging from 81% to 100% and a negative predictive value over 95% in most studies. This makes it a suboptimal diagnostic method. Measuring lactoferrin in the ascites fluid has a sensitivity of 96% and specificity of 97% with a cutoff point ≥ 242 ng/mL. Measuring serum procalcitonin (PCT) has a reported sensitivity of 86% to 95% and a specificity of 79% to 80%. Other markers previously used include pH and lactate in ascites but due to doubtful diagnoses have fallen into disuse (4, 13, 58-61). The picture for use of real-time PCR is not very encouraging. One study found bacterial DNA in 92% of the cultures that were positive for SBP and in 53% of the cultures that were negative for SBP. More than this, in most cases RT-PCR could not identify the bacterial strain. There was also disagreement between the bacteria identified by culturing and amplification techniques in this study, and RT-PCR was positive in 60% of cirrhotic patients with sterile ascites (62-64).

Cirrhotic patients have higher levels of C-reactive protein (CRP) than the general population and when infection occurs, the more severe the underlying liver dysfunction, the lower the increase in CRP. However, the constant monitoring of CRP concentrations can help determine the patient’s response to antibiotic therapy (35, 65-68).

It is essential to distinguish whether or not peritonitis is secondary to a source that is susceptible surgical treatment (48). This is important because surgical treatment increases survival rates when peritonitis is secondary, but surgery decreases survival rates for SBP (21, 48, 69). Secondary bacterial peritonitis is the cause of 5% to 10% of all peritonitis in cirrhotic patients with ascites. It should be suspected when there is inadequate response to treatment, when multiple microorganisms are isolated in a culture from ascites and when we have at least two of the Runyon criteria: glucose <50 mg/dL, total protein > 1 g/dL, and LDH > 225 mU/mL (4).

The Runyon criteria have high sensitivity (97%) but low specificity (56%), therefore other criteria have been proposed for this differential diagnosis. They include measurement of carcinoembryonic antigen and alkaline phosphatase in peritoneal fluid. When carcinoembryonic antigen levels are over 5 ng/mL, it indicates secondary bacterial peritonitis. Similarly, alkaline phosphatase levels in peritoneal fluid over 240 U/L indicate secondary bacterial peritonitis, respectively. Reported sensitivity is 92% and reported specificity is 88% (70).

**TREATMENT**

Given that culture results can take 24 to 48 hours, antibiotic therapy should be started without waiting, but, as far as possible, after taking samples (10, 11). Thus, antibiotic therapy is started empirically according to the literature.

---

**Table 1. Microbiological isolates. See references in the text.**

<table>
<thead>
<tr>
<th>Organismo</th>
<th>Bhuva et al. (51)</th>
<th>Dupeyron et al. (52)</th>
<th>do Amaral et al. (54)</th>
<th>Reginato et al. (55)</th>
<th>Bobadilla et al. (56)</th>
<th>Astencio et al. (45)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Escherichia coli</td>
<td>46</td>
<td>43</td>
<td>25.5</td>
<td>31.7</td>
<td>71.4</td>
<td>52.6</td>
</tr>
<tr>
<td>Streptococcus sp.</td>
<td>30</td>
<td>15</td>
<td>8.5</td>
<td>7.9</td>
<td>7.1</td>
<td>15.7</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>9</td>
<td>10</td>
<td>14.9</td>
<td>7.9</td>
<td>14.2</td>
<td>21</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>6</td>
<td>7</td>
<td>10.6</td>
<td>7.9</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
published on SBP and especially to the local microbiological profile.

A 2011-2013 study by the German group in Medellin found the following profiles of bacterial resistance in different hospital departments (Table 2) (71).

In general, the first-line antibiotics are third-generation cephalosporins (44, 72), except for treating SBP acquired during hospitalization which is mainly associated with enterococcus faecium and enterobacteriaceae spp. which produce extended spectrum beta-lactamase (ESBL) in which case carbapenems or tigecycline is indicated (11, 20, 73, 74).

Among the cephalosporins, the use of two grams of IV cefotaxime every 12 hours is preferred since it is associated with good concentrations in the peritoneal fluid (75-77). Ceftriaxone, but has proven to be less effective than cefotaxime. It is considered an alternative, but the fact that it has the possibility of inducing (ESBL) should be noted (78). Other options include amoxicillin with clavulanic acid (2) and fluoroquinolones including norfloxacin and ofloxacin (11). The latter should not be used in patients who have received prophylaxis for SBP using a drug from the same pharmacological group (11). Treatment should be continued until the PMN count in the ascites is below 250/mm³. On the average this occurs within five to ten days (74, 79, 80).

Therapeutic response should always be assessed in all patients through clinical follow-up and control paracentesis.

Table 2. Profile of bacterial resistance in Medellin, Colombia. See source in text.

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Antibiotic</th>
<th>Antibiotic resistance to microorganisms by hospital departments (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ICU</td>
</tr>
<tr>
<td><em>E. coli</em></td>
<td>Ampicillin</td>
<td>68.6-73.5</td>
</tr>
<tr>
<td></td>
<td>Ampicillin-Sulbactam</td>
<td>54.1-57.1</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin</td>
<td>43.3-53.3</td>
</tr>
<tr>
<td></td>
<td>Gentamicin</td>
<td>30-32.3</td>
</tr>
<tr>
<td></td>
<td>Ceftriaxone</td>
<td>17.5-19.2</td>
</tr>
<tr>
<td></td>
<td>ESBL (+)</td>
<td>10.3-14.4</td>
</tr>
<tr>
<td><em>S. aureus</em></td>
<td>Oxacillin</td>
<td>22.5-28.1</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>24.2-24.7</td>
</tr>
<tr>
<td></td>
<td>Erythromycin</td>
<td>21.7-24.7</td>
</tr>
<tr>
<td></td>
<td>Clindamycin</td>
<td>9.6-10.9</td>
</tr>
<tr>
<td><em>K. pneumoniae</em></td>
<td>Piperacillin-Tazobactam</td>
<td>24.4-26.6</td>
</tr>
<tr>
<td></td>
<td>Ceftriaxone</td>
<td>20.1-25.8</td>
</tr>
<tr>
<td></td>
<td>Ceftazidime</td>
<td>18.7-26.1</td>
</tr>
<tr>
<td></td>
<td>Aztreonam</td>
<td>19.9-27.1</td>
</tr>
<tr>
<td></td>
<td>TMP/SMX</td>
<td>15.8-23.8</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin</td>
<td>11.3-15.4</td>
</tr>
<tr>
<td></td>
<td>Meropenem</td>
<td>5.5-10.2</td>
</tr>
<tr>
<td></td>
<td>Tigecycline</td>
<td>3.9-9.5</td>
</tr>
<tr>
<td></td>
<td>ESBL (+)</td>
<td>14.1-16.2</td>
</tr>
<tr>
<td><em>E. faecalis</em></td>
<td>Gentamicin*</td>
<td>6.5-13</td>
</tr>
<tr>
<td></td>
<td>Linezolid</td>
<td>4.8-5.9</td>
</tr>
<tr>
<td></td>
<td>Ampicillin</td>
<td>0.4-2</td>
</tr>
<tr>
<td><em>E. faecium</em></td>
<td>Gentamicin*</td>
<td>16.3-34.8</td>
</tr>
<tr>
<td></td>
<td>Linezolid</td>
<td>2.1-9.4</td>
</tr>
<tr>
<td></td>
<td>Ampicillin</td>
<td>51.4-67.7</td>
</tr>
<tr>
<td><em>E. cloacae</em></td>
<td>Ceftriaxone</td>
<td>34.5-45.6</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin</td>
<td>14.5-20.3</td>
</tr>
<tr>
<td></td>
<td>TMP/SMX</td>
<td>17.2-30.2</td>
</tr>
<tr>
<td></td>
<td>Meropenem</td>
<td>8.1-16</td>
</tr>
</tbody>
</table>

* High concentration Gentamicin.
whether or not the patient has previously received quinolone prophylactically (11, 78, 85).

- Patients with impaired liver and/or kidney function who have protein concentrations of less than 15 g/dL in ascites are also at risk. Antibiotic prophylaxis with 400 mg of norfloxacin every 24 hours has been shown to reduce the risk of SBP and hepatorenal syndrome at one year, and to increase survival rates at three months and one year, for these patients (4). Other antibiotics such as rifaximin have been tried without conclusive results (17, 86). Antibiotic prophylaxis is not recommended for patients with low protein concentrations in ascites but with mild to moderate liver disease (11).

- Patients with a prior episode of SBP have a recurrence rate of 70% in the first year. Treatment with 400 mg of norfloxacin every 24 has been demonstrated to decrease this rate to 20% (11). Intermittent antibiotic prophylaxis has been suggested, but this could quickly select more resistant flora, so it should be avoided (4). It should also be noted that, due to SBP’s high mortality and recurrence rates, one episode is an indication for liver transplantation (11, 38, 44, 79, 87, 88). Prophylaxis should be continued until completion or disappearance of ascites (81).

### ANTIBIOTIC PROPHYLAXIS

Because of the costs involved and the potential for development of bacterial resistance, antibiotic prophylaxis should be considered only for patients who are at high risk of developing SBP (Table 3). Bacterial resistance is increasing. In the case of quinolone, resistance has been documented in up to 50% of Gram-negative bacteria isolated from patients who have received prophylaxis with norfloxacin as opposed to in only 16% of those who did not receive prophylaxis. In the case of TPM/SMX, resistance has been documented in samples from 44% of patients who are treated while it has been found in only 16% of those who are not (72, 83).

The following list shows factors considered high risks for development of SBP (44, 84):

- Patients with cirrhosis who have gastrointestinal bleeding have 25% to 65% probability of developing a bacterial infection including pneumonia, urinary tract infections and/or SBP within seven days. An additional infection in one of these patients increases the risk of rebleeding (4). In this patient group, 400 mg every 12 hours of oral norfloxacin or one gram of IV ceftriaxone IV every 24 hours is recommended as antibiotic prophylaxis depending on the severity of cirrhosis and on whether or not the patient has previously received quinolone prophylactically (11, 78, 85).

#### Table 3. Indications for prophylaxis and recommended schemes. See references in the text.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhotic patients with gastrointestinal bleeding</td>
<td>400 mg Norfloxacin every 12 hours Nasal-gastric tube 1 gram IV Ceftriaxone every 24 hours</td>
</tr>
<tr>
<td>Patients with prior episode of SBP</td>
<td>400 mg oral Norfloxacin every 24 hours</td>
</tr>
<tr>
<td>Patients with low protein concentration in ascites (≤15 g/dL)</td>
<td>400 mg oral Norfloxacin every 24 hours 500 mg oral ciprofloxacin every 24 hours 1 gram IV Ceftriaxone every 24 hours 550 mg oral rifaximin every 12 hours 160/800 mg TMP/SMX daily for 5 days</td>
</tr>
<tr>
<td>Patients with Child-Pugh C or Serum Cr &gt; 1.5 mg/dL</td>
<td>Not recommended</td>
</tr>
<tr>
<td>Patients with Child-Pugh A or B</td>
<td></td>
</tr>
</tbody>
</table>

SNG: sonda nasogástrica; Cr: creatinina.
and ascites and to the amplified proinflammatory response which worsens circulatory dysfunction in cirrhotic patients and subsequently leads to renal hypoperfusion (90, 91).

The use of intravenous albumin to prevent hepatorenal syndrome has been studied. Doses of 1.5 g/kg at diagnosis followed by 1 g/kg at 72 hours have reduced incidence to 10%. Similarly, the addition of albumin to antibiotic therapy has led to a decrease in the mortality rate from 29% to 10% (11, 92). The principal use of albumin has been observed in patients with total bilirubin over four mg/dL and serum creatinine over one mg/dL. It has reduced both the mortality rate and the incidence of hepatorenal syndrome (91, 93).

KEY ISSUES

- **SBP** is one of the most feared complications in cirrhotic patients because of its high rate of recurrence and high mortality rate. It should be suspected in all cirrhotic patients with ascites, and especially if accompanied by fever, abdominal pain, encephalopathy and impaired hepatic and/or renal function. The most important measure is early diagnosis and prompt treatment.

- **Diagnosis:** ≥250 neutrophils/mm³. Also cell chemistry, Gram stain, and culture of ascites are required.

- **Treatment** starts immediately after sampling: Two g IV Cefotaxime every 12 hours for 8 days unless nosocomial infection is suspected, in which case treatment should be one g IV Meropenem every 8 hours.

- **Bacteriascitis:** <250 neutrophils/mm³, culture of ascitic fluid tests positive. Manage like SBP.

- **Prophylaxis:** 400 mg oral norfloxacin every 24 hours.
  - For patients with previous episode of SBP
  - For patients with gastrointestinal bleeding administration through a nasa-gastric tube every 12 hours is recommended.
  - For patients with Child-Pugh C cirrhosis with ascites protein less than 5 g/dL
  - SBP is a criterion for liver transplantation since transplantation resolves the acute situation and the patient is stabilized.

Acknowledgements

The authors thank the Sustainability Project of the Vice-Rector for Research at the University of Antioquia.

REFERENCES

46. Salinas Gómez DC. Caracterización clínica, citoquímica y microbiológica de pacientes cirróticos con peritonitis bacteriana en la Fundación Cardioinfantil. 2014.
47. Runyon BA, Canawati Hn Fau - Akriviadis EA, Akriviadis EA. Optimization of ascitic fluid culture technique. (0016-5085 (Print)).
50. Rubinstein Aguñín P, Bagattini JC. Aspectos microbiológicos de interés en el diagnóstico de la peritonitis bacteriana.


